

PRESS RELEASE

TORSKAL extends its know-how in analysis and research services in various scientific fields.

Paris, France: July 04, 2022

The biotech company offers scientific research services in nanotechnology, biology, phytochemistry and others.

With nearly 7 years of experience in scientific research and development, TORSKAL has developed superior expertise in various fields, including nanotechnology, biology, phytochemistry, etc. With this expertise, TORSKAL offers research services in the mentioned fields and hopes to support its potential customers in meeting their project needs.

TORSKAL's scientific team is composed of highly qualified researchers who have access to two fully equipped laboratories, one located at the company's headquarters in Reunion Island and the other in its Paris office.

Nanotechnology and biology being the core fields of the company, it offers nanotechnology services for the design of nanoparticles, their coating with specific molecules and their nanocaracterization. In the field of biology, it offers preclinical *in vitro* and *in vivo* tests for efficacy, toxicity and biodistribution studies. Likewise, phytochemistry research services are offered for phytochemical characterization, antiradical activity testing and antibacterial and antifungal activity testing.

In addition to these in-house research services, TORSKAL also offers environmental and biological research services in partnership with its partner companies, through their mutual technical and intellectual support.

TORSKAL, which has recently expanded its product portfolio, is now entering a new phase with the launch of its research services. The company is also preparing to enter the clinical phase with its NT1 project to treat skin cancer using its patented green synthesized gold nanoparticles combined with photothermal therapy (PTT).

PRESS RELEASE

About TORSKAL:

The French company was founded in 2015 by two scientists, Anne-Laure Morel, chief scientific officer and president, the inventor of the technology, and Christophe Dugué, managing director and head of regulatory affairs and intellectual property, who joined the company in 2016. The company was founded with the goal of developing green nanoscience from ethical and responsible gold and medicinal plants. Virginie Simon, General Director joined the executive team in 2020 to develop the company internationally.

TORSKAL is a pioneer in green nanotechnology, a precursor in the green chemistry design of new cancer treatments from gold nanoparticles that are produced from a patented method. Their invention is protected by a patent filed in 40 countries covering the synthesis process, the product, and applications in oncology and dermocosmetics.

Their first and main program, the Nanotheranostics - NT1 project aims at treating skin cancers by photothermal therapy, which is a class 3 medical device made of their patented gold nanoparticles designed by green chemistry. The project will enter clinical trials in 2022.

TORSKAL promotes the use of green nanotechnology in therapy and diagnostics, and in industry in general. As a member of the French delegation to the G20YEA, the company is working to ensure that green nanoscience emerges in a sustainable way for the reconstruction of tomorrow.

More information about [TORSKAL](#)

More information about TORSKAL's [research services](#)